Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[225Ac]Ac-DOTATATE + Tislelizumab in ES-SCLC
NCT07413042Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of actinium-225 dotatate in small cell lung cancer (SCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Efficacy of [225Ac]Ac-DOTATATE injection at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
actinium-225 dotatate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07413042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413042.